On April 19, Anhui Huaheng Biotechnology Co.Ltd(688639) released its annual report for 2021. The company achieved an operating revenue of 954 million yuan, an increase of 95.81% year-on-year; The net profit attributable to shareholders of listed companies was 168 million yuan, a year-on-year increase of 38.92%.
It is reported that as one of the leading enterprises in the field of synthetic biology, the company has built the leading technology advantages of the whole industrial chain, such as industrial strain creation, intelligent control of fermentation process, efficient separation and extraction and product application development. The company broke through the bottleneck of anaerobic fermentation technology and successfully realized the large-scale production of L-alanine by microbial anaerobic fermentation for the first time in the world. It is one of the advantageous enterprises in the industry with complete intellectual property rights for the production of L-alanine by anaerobic fermentation.
During the reporting period, the company attached great importance to technological innovation and the accumulation of independent intellectual property rights. Focusing on the two major production processes of fermentation and enzyme, the company gradually began to layout other products in the field of synthetic biology, forming a core technology cluster related to synthetic biotechnology.
During the reporting period, the company’s fund-raising project Bayannur alternating production of alanine and valine project and Qinhuangdao fermentation alanine technological transformation and expansion project were partially put into operation as planned, the capacity utilization was released and improved in an orderly manner, and the economy of relevant products was gradually presented. Bayannur’s alternating production of alanine and valine was partially put into operation, further enriching the company’s product types, enhancing the company’s core competitiveness in the field of animal nutrition, and taking a solid step in the diversified expansion of the company’s main business; The expansion of alanine production by fermentation in Qinhuangdao further consolidated the company’s leading position in alanine related industries, and its competitive advantage became more and more prominent.
During the reporting period, the company realized fermentation production β- Arbutin technology industrialization, and the company’s biological enzyme method α- Arbutin products complement each other and provide better product services for customers in the downstream cosmetics industry. Arbutin products, as a component of high-efficiency whitening products, are mainly added to whitening cosmetics.
During the reporting period, the company further strengthened its technological leadership in the whole industrial chain, such as industrial strain creation, intelligent control of fermentation process, efficient separation and extraction and product application development, and further improved the fermentation production process with microbial cell factory as the core and enzyme catalysis as the core.
The annual report shows that in the next step, the company will continue to steadily promote key fund-raising and investment projects, three branched chain amino acids and derivatives project of Bayannur base and beta alanine derivatives project of Changfeng base, improve product capacity, improve three branched chain amino acid product types, open up upstream technologies of relevant products, improve the integration of industrial chain and continuously enhance the comprehensive competitiveness of products. At the same time, the company will continue to increase high investment in R & D in the future, accelerate the development of more kinds of bio based new products, and promote China’s leapfrog development in the field of biological manufacturing.
Anhui Huaheng Biotechnology Co.Ltd(688639) said that in the future, the company will adhere to the development path of “two alternatives”, namely “replacing non renewable petrochemical resources with renewable biological resources” and “replacing petrochemical processes with high energy consumption and high pollution with green and clean biological manufacturing processes”, so as to achieve the goal of modern biological manufacturing enterprises “driven by scientific and technological innovation and based on advanced manufacturing capacity”.
